ArticleAllergy, asthma & immunology research2026
Efficacy of Starting Very-Low-Dose Cow's Milk Intake in Children Aged 1-12 Years With Severe Cow's Milk Allergy: A Retrospective Study.
Article in Allergy, asthma & immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo avoid the complete elimination of cow's milk (CM) from the diet, we introduced a very-low-dose (VLD) oral food challenge (OFC) as part of an OFC-based stepwise ingestion protocol in patients with severe CM allergy in 2019, when the OFC protocol at our center was revised. This study investigated the efficacy of initiating CM intake through an OFC-based stepwise ingestion protocol starting from a VLD in achieving a negative full-dose OFC.
methodsPatients with a history of overt allergic reactions to low-dose (LD; 3 mL CM: 100 mg CM protein) CM or lesser within 6 months and those with complete CM elimination were included. We retrospectively compared the rate of passing a full-dose OFC (200 mL CM: 6,600 mg CM protein) between patients who underwent an LD OFC before 2019 (LD group) and those who underwent a VLD OFC (0.3 mL CM: 10 mg CM protein) after 2019 (VLD group). The period for passing the full-dose OFC was evaluated using Kaplan-Meier survival analyses.
resultsWe allocated 270 and 267 patients into the LD and VLD groups, respectively. The median age at initiation of the OFC-based stepwise ingestion protocol was 3.6 (2.3-5.4) and 3.4 (2.0-5.1) years in the LD and VLD groups, respectively. The LD and VLD groups had CM-specific immunoglobulin E levels of 21.9 (10.9-44.0) kUA/L and 20.5 (9.0-47.2) kUA/L, respectively. The baseline clinical characteristics of the two groups showed no significant differences in background. Over 4 years, the LD and VLD groups passed the full-dose OFC at rates of 45% and 60%, respectively, with a significant difference (log-rank test,
conclusionsInitiating CM intake through an OFC-based stepwise ingestion protocol starting from a VLD may contribute to achieving a negative full-dose OFC in patients with severe CM allergies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.